These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 12652962

  • 1. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV, Chimishkian KL, Zhukov NV, Osmanov DSh, Andreeva LIu, Tupitsyn NN, Larionova VB, Mkheidze DM, Poddubnaia NV.
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 3. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 7. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
    Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D.
    Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
    [Abstract] [Full Text] [Related]

  • 8. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M.
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P, Dray L, Resnick IB, Ackerstein A, Gesundheit B, Elad S, Or R, Shapira MY.
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
    Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet AS, Traulle C, Bouafia-Sauvy F, Giraud C, Salles G, Guilhot F, Coiffier B.
    Cancer; 2005 Oct 01; 104(7):1434-41. PubMed ID: 16104036
    [Abstract] [Full Text] [Related]

  • 12. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
    Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C.
    Ann Hematol; 2006 Nov 01; 85(11):769-79. PubMed ID: 16896912
    [Abstract] [Full Text] [Related]

  • 13. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
    Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N, Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Biol Blood Marrow Transplant; 2010 May 01; 16(5):672-7. PubMed ID: 20045738
    [Abstract] [Full Text] [Related]

  • 14. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D, Luger S, Schuster S, Stadtmauer E.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):521-6. PubMed ID: 10482937
    [Abstract] [Full Text] [Related]

  • 15. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec 01; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 16. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul 01; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 17. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug 15; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.
    Ai Zheng; 2004 Dec 15; 23(12):1681-6. PubMed ID: 15601560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.